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All cells die, but the manner of death dictates interactions with living cells and consequences for the
organism, especially with respect to the immune response. Here we discuss the different modes of cell death
as they relate to this rapidly evolving field.Introduction
The study of cell death represents some-
thing of a paradigm shift in recent years.
Cell death was first described in the 19th
century in the writings of Virchow and
Ramon y Cajal, and the theme re-
emerged sporadically throughout much
of the 20th century. Research in the field
was languid, however, even after apo-
ptosis was defined as a distinct and active
process, a biochemical marker (DNA frag-
mentation) was identified, and it was
demonstrated that developmental cell
death is genetically controlled. It was not
until the 1990s that the study of the
molecular basis of cell death flourished,
and over the past 20 years we saw an ex-
plosion of interest in the subject. In a
sense, the slow paradigm shift was from
‘‘obvious’’ (cells die) to ‘‘somewhat inter-
esting’’ (cells seem to die on a schedule)
to ‘‘profound’’ (novel, regulated molecular
processes mediate and define distinct
pathways of cell death). Known through-
out was that dying cells only sometimes
elicit inflammatory responses, and it was
not until different forms of cell death
were distinguished that we realized that
the type of death actually matters to
the physiology and pathology of the
organism.
The reviews in this issue focus on cell
death and the immune system, or more
precisely, on how dying cells impact
physiology through their interactions
with components of the immune system.
These reviews explore four areas of inten-
sive investigation revolving around these
interactions and their consequences in
mammals. The rapid engulfment of dying
cells and the molecular events controlling
their clearance is discussed in this issue
by Ravichandran. The impact of such
clearance on the adaptive immuneresponse is then considered by Griffith
and Ferguson, and the resulting impact
on the response to infection, and in turn,
the coevolution of evasion mechanisms
by infectious organisms is outlined by
Yatim and Albert. Finally, Kuraishy et al.
consider how dying cells, and the altered
inflammatory milieu, contribute to
oncogenesis.
Active versus Passive Cell Death
Three types of cell death, based on the
morphologies of the dying cells, have
been broadly recognized. While other
types of cell death have been suggested,
a recent survey has proposed that these
three be generally adopted. These are
Type I, or apoptotic cell death; Type II,
or ‘‘autophagic’’ cell death; and Type III,
or necrotic cell death (a fourth type, cor-
nification, is also recognized, but is re-
stricted to a single cell type, the keratino-
cyte). Until recently, the first two types
were considered ‘‘active,’’ that is, con-
trolled by molecular processes that not
only dictate the morphology but also
determine the fate of the cell. Necrosis
(Type III) was considered ‘‘passive,’’ a
consequence of damage so extensive
that the cell cannot survive. As we will
see, we now realize that there are forms
of active necrosis as well.
Another attempt at classification relies
on the consequences of cell death, and
again, until recently, necrosis was viewed
as ‘‘inflammatory and immunogenic’’
whereas apoptosis was considered
immunologically ‘‘silent, or actively tolero-
genic.’’ More current evaluations have
modified this simple framework (Ullrich
et al., 2008) as we have come to realize
that the specific triggers for cell death or
the presence of microbial products can
result in immunogenic apoptosis. The
immunologic consequences of Type IIImmunity 35cell death are less well understood, in
part because (as discussed below) the
nature of this type of cell death itself is
only poorly elucidated in mammals.
Pathways of Cell Death
Type I. Apoptosis
Apoptosis is characterized by chromatin
condensation and often involves plasma
membrane blebbing and fragmentation
of the cell into membrane-enclosed
bodies. This process is orchestrated
by a set of proteolytic enzymes, cysteine
proteases with specificity for aspartic
acid residues in their substrates, or cas-
pases. The executioner caspases (cas-
pases-3, -6, and -7) cleave at least 1,000
substrates in the cell, and it is the
cleavage of such substrates that causes
the changes associated with apoptosis.
These executioner caspases are inactive
dimers in the cell until cleaved at specific
sites, and this cleavage is mediated by
the initiator caspases. In contrast to the
executioner caspases, the initiator cas-
pases are activated by adaptor molecules
that bring the inactive caspasemonomers
into close proximity on ‘‘caspase activa-
tion platforms.’’ The specific adapters
and initiator caspases, and the resultant
activation platforms, define the pathways
of apoptosis.
Simplified schemes for four different
(but often interconnected) apoptotic path-
ways are shown in Figure 1. More detailed
descriptions of these pathways are re-
viewed elsewhere (Green, 2011). The
mitochondrial pathway, the most preva-
lent route to cell death in mammals, is
controlled by proteins of the BCL-2 family,
a family of proteins that as their primary
function regulate the integrity of the mito-
chondrial outer membrane. These pro-
teins are expressed and/or modified in, October 28, 2011 ª2011 Elsevier Inc. 441
Figure 1. Pathways to Apoptosis
Four routes to caspase activation that can result in apoptosis are shown. In each, the formation of a cas-
pase activation platform brings an initiator caspase monomer into proximity, promoting their activation. In
the death receptor pathway (top left), ligation of death receptors of the TNFR superfamily recruits an
adaptormolecule, FADD, forming an activation platform for caspase-8, called the death inducing signaling
complex (DISC). In the mitochondrial pathway (top right), a variety of cellular stresses induce expression
and/or modification of proapoptotic proteins of the BCL-2 family, which promote mitochondrial outer
membrane permeabilization (MOMP). Cytochrome c, released to the cytosol, triggers the oligomerization
of an adaptor protein, APAF1, forming an activation platform for caspase-9, called the apoptosome. In the
caspase-1 pathway (bottom left), pathogen- or damage-associated molecular patterns (PAMPS, DAMPS)
engage cell surface or intracellular pattern recognition receptors (PRR), which signal to or directly promote
the assembly of adaptor proteins, such as ASC, into an activation platform for caspase-1. This is called the
inflammasome. In addition to potentially promoting apoptosis, caspase-1 also processes the cytokines
IL-1b and IL-18 and promotes secretion of these and other inflammatory mediators. In the caspase-2
pathway (bottom right), some cellular stresses induce the assembly of an adaptor protein, RAIDD, into
an activation platform for caspase-2, called the piddosome (as it often contains another protein, PIDD).
If activated in sufficient amounts, the initiator caspases can process and thereby activate executioner cas-
pases, resulting in apoptosis. Alternatively, caspases-1, -2, and -8 often must engage the mitochondrial
pathway through cleavage and activation of a BCL-2 family protein, in order to promote apoptosis.
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and interact to cause outer mitochondrial
membrane permeabilization (MOMP).
Proteins released from the mitochondrial
intermembrane space include cyto-
chrome c (which induces oligomerization
of APAF-1, the adaptor protein in this
pathway), engaging and activating the
initiator caspase, caspase-9 (other re-
leased proteins facilitate caspase activa-
tion). The death receptor pathway in-
volves a subset of the tumor necrosis
factor receptor (TNFR) superfamily, which
upon ligation induce oligomerization of
another adaptor, FADD, which activates442 Immunity 35, October 28, 2011 ª2011 Elthe initiator caspase-8. Another pathway
is engaged in response to pathogen- or
damage-associated molecular patterns,
‘‘PAMPS’’ and ‘‘DAMPS,’’ respectively,
triggering the assembly of adaptor pro-
teins for caspase-1, thereby activating it
(there are several adaptor proteins for
caspase-1, the major one being ASC).
Finally, some cellular stresses, including
heat shock, microtubule disruption, and
some forms of metabolic stress, engage
an adaptor molecule (RAIDD) for the acti-
vation of caspase-2. While caspase-8,
caspase-1, and perhaps caspase-2 can
directly cleave and activate executionersevier Inc.caspases, inmany cells theymust engage
the mitochondrial pathway to do so effec-
tively (which they do by cleavage and
activation of one of the BCL-2 family
proteins).
For our purposes here, three distinct
‘‘modes’’ of apoptosis should be noted.
Apoptosis can proceed with or without
MOMP, which exposes the mitochondrial
inner membrane to proteolysis, thereby
disrupting the organelle to release and/
or modify DAMPs (discussed in more
detail by Griffith and Ferguson in this
issue). In addition to these two modes,
a third mode includes the activation of
caspase-1, which can cause cell death,
but can independently function to pro-
cess the inflammatory cytokines inter-
leukin-1 and interleukin-18 and engage
a nonclassical secretory pathway for the
release of these and other inflammatory
mediators. (Another mode, that of cas-
pase-2 activation without MOMP, has
not been analyzed in terms of immuno-
logic consequence.)
Type II. ‘‘Autophagic’’ Cell Death
Type II cell death is triggered in response
to certain drugs, including agents that
disrupt lysosomes, and can also occur in
response to developmental and tumor-
suppressor signals. It is morphologically
defined as distinct from apoptosis, with
cells displaying large vacuoles (probably
enlarged lysosomes) and engagement of
autophagy. Autophagy is the process of
‘‘self eating’’ in which double membrane
vesicles form de novo, engulfing cyto-
plasmic components for degradation
upon fusion with lysosomes. In general,
the autophagic process (reviewed in
detail elsewhere, e.g., Singh and Cuervo,
2011) promotes cell survival, and inhibi-
tion of autophagy causes more cell death
under Type II conditions. Thus, this form
of cell death is often suggested to be
‘‘cell death with accompanying auto-
phagy’’ (Maiuri et al., 2007).
In addition, Type II cell death that
actually depends on elements of the auto-
phagy pathway has been described. This
is best characterized in Drosophila meta-
morphosis (Ryoo and Baehrecke, 2010),
although examples in mammalian cells
also exist (Elgendy et al., 2011). At this
point, it may be simplistic to suggest
that this form of cell death occurs as a
consequence of ‘‘too much autophagy,’’
that is, involvement of elements of the
autophagy pathway does not necessarily
Figure 2. Pathways to ‘‘Programmed Necrosis’’
Necrosis can be passive, occurring as a consequence of excessive cell damage or catastrophic loss of
energy. However, necrosis can also be an active process. Two such mechanisms are illustrated. In
RIPK-dependent necrosis (left), ligating death receptors or some TLRs (TLR3 or TLR4) activates a kinase,
RIPK1, which in turn binds to a related kinase, RIPK3, triggering necrosis. Precisely how RIPK3 causes
necrosis is not known. In the mitochondrial pathway of necrosis (right), injury (such as ischemia plus reper-
fusion) causes elevation of calcium and/or reactive oxygen species (ROS). These impact the mitochondria
to cause a sudden change in permeability of the inner membrane to small solutes (mitochondrial perme-
ability transition, MPT). Efficient MPT requires the matrix protein cyclophilin D (CYPD). As a consequence
of MPT, mitochondrial transmembrane potential is lost and the matrix swells, damaging the mitochondria.
Death ensues as a consequence of energetic catastrophe or through active damage by mitochondrial
products or contents. Two modes of active necrosis, not shown here (see text), are caspase-independent
cell death (CICD, a consequence of MOMP induced by BCL-2 proteins, proceeding in the absence of
caspases) and secondary necrosis, a consequence of failure to clear apoptotic cells.
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the cell in this setting. The precise mech-
anisms responsible for such cellular
demise remain to be elucidated.
From our perspective here, the paucity
of information on immune consequences
of Type II cell death somewhat precludes
further discussion. It should be noted,
however, that autophagy appears to
impact inflammatory (Levine et al., 2011)
and adaptive immune responses as dis-
cussed by Yatim and Albert in this issue.
This may or may not relate to Type II cell
death.
Type III. Necrosis
Necrosis is characterized by a loss of
plasmamembrane integrity, accompanied
by organellar (e.g., endoplasmic reticulum
and mitochondria) swelling, usually with-
out nuclear condensation (except in one
case, discussed below). It can be caused
by excessive damage and/or catastrophic
energy loss, and thus can be a passive
process, as we noted above. Recent evi-
dence has shown, however, that necrosis
can be the result of regulated processes
and therefore, in a sense, ‘‘programmed.’’
Two pathways of programmed necrosis
are outlined in the simplified scheme
shown in Figure 2. These and other path-
ways of necrosis are reviewed in more
detail elsewhere (Green, 2011).
One active process involved in some
forms of necrosis is the mitochondrialpermeability transition (MPT), which is
distinct from MOMP in apoptosis. Al-
though only partially understood, MPT
involves the mitochondrial matrix protein
cyclophilin D (CYPD) and results in
sudden loss of mitochondrial transmem-
brane potential and matrix swelling. It
can result from high levels of calcium
and/or reactive oxygen species, such as
are seen in ischemia/reperfusion injury.
Indeed, animals deficient in CYPD, al-
though displaying no defects in apo-
ptosis, are resistant to necrosis induced
by ischemia/reperfusion (Leung and Hale-
strap, 2008).
Another form of programmed necrosis
occurs via the action of two kinases:
receptor interacting protein kinase-1
(RIPK1) and RIPK3. These are engaged
by ligation of death receptors (see above)
or by Toll-like receptor 3 (TLR3) and TLR4.
It can also occur as a consequence of
DNA damage, apparently independently
of surface receptors (Green et al., 2011).
They are inhibited by some caspases (in
particular, caspase-8) and therefore this
form of necrosis can manifest under
some conditions of caspase inhibition.
The mechanisms by which RIPK1 and
RIPK3 cause necrosis are under active
investigation. This RIPK-dependent ne-
crosis (sometimes called ‘‘necroptosis’’)
is frequently equated with Type II (auto-
phagic) cell death. However, no role forImmunity 35autophagy (as inducer, effector, or regu-
lator of this form of necrosis) has been
unambiguously elucidated (Maiuri et al.,
2007).
Necrosis also occurs if MOMP, regu-
lated by the BCL-2 proteins (see above),
proceeds in the absence of caspase
activation (as a consequence of inhibitors
or ablation of the downstream pathway).
This caspase-independent cell death
(CICD) appears to be the result of a loss
of mitochondrial function or may be
caused by other mediators released from
the mitochondria (reviewed elsewhere;
Green, 2011).
Importantly for our discussion here,
necrosis also occurs if a cell dying by
apoptosis is not rapidly engulfed and
cleared. This ‘‘secondary necrosis’’ is
distinct from other forms of necrosis in
that the chromatin condensation, charac-
teristic of apoptosis, is seen in this form
of death. Failure to clear apoptotic cells,
and the ensuing secondary necrosis, is
thought to contribute to autoimmune
diseases such as systemic lupus
erythematosis.
Although necrotic cells and their asso-
ciated DAMPs are generally thought to
be proinflammatory and immunogenic, it
is not knownwhether the pathway leading
to necrosis affects the inflammatory or
immunologic outcome.
Coda: In Memorium
Dying cells impact the organism through
their interactions with living cells. Our
focus, in large part, is on those interac-
tions that affect the immune system and
consequences of this interaction in
nonimmune tissues, such as occurs in
cancer.
While considering these effects, we
shouldbeaware thatother typesof interac-
tions between dying and living cells may
well exist. In arthropods, a process called
‘‘compensatory proliferation’’ has been
elucidated, in which dying cells stimulate
proliferation of neighboring cells (Fan and
Bergmann, 2008). This process depends
on caspase activity in the dying cells and
appears to be mediated via TGF-b and
WNT family proteins. Although not exten-
sively described in mammalian systems,
evidence supports the idea that dying cells
can inducestemcelldifferentiation (Li etal.,
2010). The role of the immune and/or
inflammatory response in such effects
may prove interesting., October 28, 2011 ª2011 Elsevier Inc. 443
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impact on the immune system of cells
that have not died but have undergone
senescence. Such cells, like dying cells,
are cleared from the body and produce
mediators that facilitate such clearance
(e.g., Coppe´ et al., 2008). It is not unlikely
that they influence immune responses in
the process.
In any case, it is clear that when cells
die they are not ‘‘forgotten.’’ How dying
cells impact their surroundings is a rich
field of investigation, as the reviews that
follow amply illustrate.
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